Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Magali Lacroix

Showing results (101-110 of 117) with videos related to

Pageof 12
Sort By:
Nature Communications|July 29, 2025
Autocrine interferon poisoning mediates ADAR1-dependent synthetic lethality in BRCA1/2-mutant cancersRoman M Chabanon, Liudmila Shcherbakova, Magali Lacroix-Triki, et al.
Annales De Pathologie|November 9, 2010
[Update of the GEFPICS' recommendations for HER2 status determination in breast cancers in France]Frédérique Penault-Llorca, Anne Vincent-Salomon, Jean-Pierre Bellocq, et al.
Nature Medicine|January 19, 2023
Federated learning for predicting histological response to neoadjuvant chemotherapy in triple-negative breast cancerJean Ogier du Terrail, Armand Leopold, Clément Joly, et al.
Annales De Pathologie|July 2, 2019
[GEFPICS' guidelines for management of breast cancer tissue samples in the neoadjuvant setting]Aurélie Maran-Gonzalez, Camille Franchet, Raphaëlle Duprez-Paumier, et al.
Laboratory Investigation; a Journal of Technical Methods and Pathology|May 10, 2024
Fit-for-Purpose Ki-67 Immunohistochemistry Assays for Breast CancerEmina E Torlakovic, Nick Baniak, Penny J Barnes, et al.
Nature Medicine|July 24, 2023
Trastuzumab deruxtecan in metastatic breast cancer with variable HER2 expression: the phase 2 DAISY trialFernanda Mosele, Elise Deluche, Amelie Lusque, et al.
BMC Cancer|July 24, 2013
SISH/CISH or qPCR as alternative techniques to FISH for determination of HER2 amplification status on breast tumors core needle biopsies: a multicenter experience based on 840 casesJocelyne Jacquemier, Frédérique Spyratos, Benjamin Esterni, et al.
Plos Medicine|December 28, 2016
Mutational Profile of Metastatic Breast Cancers: A Retrospective AnalysisCeline Lefebvre, Thomas Bachelot, Thomas Filleron, et al.
Annales De Pathologie|August 16, 2021
[2021 update of the GEFPICS' recommendations for HER2 status assessment in invasive breast cancer in France]Camille Franchet, Lounes Djerroudi, Aurélie Maran-Gonzalez, et al.
Annales De Pathologie|December 3, 2014
[Pre-analytical stage for biomarker assessment in breast cancer: 2014 update of the GEFPICS' guidelines in France]Gaëtan MacGrogan, Marie-Christine Mathieu, Bruno Poulet, et al.
Pageof 12

Showing results (101-110 of 117) with videos related to

Sort By:
Pageof 12
Nature Communications|July 29, 2025
Autocrine interferon poisoning mediates ADAR1-dependent synthetic lethality in BRCA1/2-mutant cancersRoman M Chabanon, Liudmila Shcherbakova, Magali Lacroix-Triki, et al.
Annales De Pathologie|November 9, 2010
[Update of the GEFPICS' recommendations for HER2 status determination in breast cancers in France]Frédérique Penault-Llorca, Anne Vincent-Salomon, Jean-Pierre Bellocq, et al.
Nature Medicine|January 19, 2023
Federated learning for predicting histological response to neoadjuvant chemotherapy in triple-negative breast cancerJean Ogier du Terrail, Armand Leopold, Clément Joly, et al.
Annales De Pathologie|July 2, 2019
[GEFPICS' guidelines for management of breast cancer tissue samples in the neoadjuvant setting]Aurélie Maran-Gonzalez, Camille Franchet, Raphaëlle Duprez-Paumier, et al.
Laboratory Investigation; a Journal of Technical Methods and Pathology|May 10, 2024
Fit-for-Purpose Ki-67 Immunohistochemistry Assays for Breast CancerEmina E Torlakovic, Nick Baniak, Penny J Barnes, et al.
Nature Medicine|July 24, 2023
Trastuzumab deruxtecan in metastatic breast cancer with variable HER2 expression: the phase 2 DAISY trialFernanda Mosele, Elise Deluche, Amelie Lusque, et al.
BMC Cancer|July 24, 2013
SISH/CISH or qPCR as alternative techniques to FISH for determination of HER2 amplification status on breast tumors core needle biopsies: a multicenter experience based on 840 casesJocelyne Jacquemier, Frédérique Spyratos, Benjamin Esterni, et al.
Plos Medicine|December 28, 2016
Mutational Profile of Metastatic Breast Cancers: A Retrospective AnalysisCeline Lefebvre, Thomas Bachelot, Thomas Filleron, et al.
Annales De Pathologie|August 16, 2021
[2021 update of the GEFPICS' recommendations for HER2 status assessment in invasive breast cancer in France]Camille Franchet, Lounes Djerroudi, Aurélie Maran-Gonzalez, et al.
Annales De Pathologie|December 3, 2014
[Pre-analytical stage for biomarker assessment in breast cancer: 2014 update of the GEFPICS' guidelines in France]Gaëtan MacGrogan, Marie-Christine Mathieu, Bruno Poulet, et al.
Pageof 12